O’Brien, S., Patel, M., Kahl, B. S., Horwitz, S. M., Foss, F. M., Porcu, P., . . . Flinn, I. (2018). Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol.
Citação norma ChicagoO’Brien, Susan, et al. "Duvelisib, an Oral Dual PI3K-δ,γ Inhibitor, Shows Clinical and Pharmacodynamic Activity in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in a Phase 1 Study." Am J Hematol 2018.
MLA citiranjeO’Brien, Susan, et al. "Duvelisib, an Oral Dual PI3K-δ,γ Inhibitor, Shows Clinical and Pharmacodynamic Activity in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in a Phase 1 Study." Am J Hematol 2018.